Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults

被引:28
作者
Escribano, L [1 ]
Agustín, BD [1 ]
Bravo, P [1 ]
Navalón, R [1 ]
Almeida, J [1 ]
Orfao, A [1 ]
机构
[1] Univ Alcala de Henares, Hosp Ramon y Cajal, Dept Hematol, Madrid, Spain
关键词
systemic mast cell disease; aberrant immunophenotype; bone marrow; diagnosis;
D O I
10.3109/10428199909145725
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One of the major advances in the histological diagnosis of bone marrow (BM) involvement in mastocytosis has been the specific immunohistochemical detection of tryptase on most cells (MC), which has shown to be of great diagnostic value, especially in cases of malignant mastocytosis. On the other hand, recent studies have clearly shown that bone marrow mast cells can be specifically identified and accurately enumerated using multiparametric flow cytometry, which allow a systematic analysis of the immunophenotypic characteristics of bone marrow mast cells. Once this flow cytometric approach was applied for the analysis of BMMC from mastocytosis patients clear immunophenotypical differences were found between BMMC from normal individuals and adults with mastocytosis, The most characteristic immunophenotypic feature, both in malignant and adult indolent systemic mast cell disease, being the coexpression of CD2 and CD25 antigens, never present in normal bone marrow mast cells and, which constitute an aberrant hallmark of bone marrow mart cells in adult mastocytosis. Furthermore, bone mast cells from mastocytosis display a higher reactivity for CD35, CD63, and CD69 activation-associated antigens. Based on these results it could be concluded that the use of multiparametric flow cytometric immunophenotyping of BMMC in adult patients suffering from cutaneous mastocytosis can be of great utility for the diagnosis of BM involvement; additionally, this might also help to establish the real incidence of BM involvement in cutaneous mastocytosis.
引用
收藏
页码:227 / 235
页数:9
相关论文
共 63 条
[1]   Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes [J].
Agis, H ;
Fureder, W ;
Bankl, HC ;
Kundi, M ;
Sperr, WR ;
Willheim, M ;
BoltzNitulescu, G ;
Butterfield, JH ;
Kishi, K ;
Lechner, K ;
Valent, P .
IMMUNOLOGY, 1996, 87 (04) :535-543
[2]  
Baghestanian M, 1996, LEUKEMIA, V10, P159
[3]  
Brunning RD, 1994, TUMORS BONE MARROW, P409
[4]   ESTABLISHMENT OF AN IMMATURE MAST-CELL LINE FROM A PATIENT WITH MAST-CELL LEUKEMIA [J].
BUTTERFIELD, JH ;
WEILER, D ;
DEWALD, G ;
GLEICH, GJ .
LEUKEMIA RESEARCH, 1988, 12 (04) :345-355
[5]  
CASTELLS MC, 1987, J IMMUNOL, V138, P2184
[6]   MAST-CELL LEUKEMIA - EVIDENCE FOR BONE-MARROW ORIGIN OF THE PATHOLOGICAL CLONE [J].
DALTON, R ;
CHAN, L ;
BATTEN, E ;
ERIDANI, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (02) :397-406
[7]  
Davidson G, 1993, Qual Health Care, V2, P21
[8]  
DEBATIN KM, 1989, LEUKEMIA, V3, P566
[9]  
DVORAK AM, 1985, LAB INVEST, V53, P45
[10]   Indolent systemic mast cell disease in adults:: Immunophenotypic characterization of bone marrow mast cells and its diagnostic implications [J].
Escribano, L ;
Orfao, A ;
Díaz-Agustin, B ;
Villarrubia, J ;
Cerveró, C ;
López, A ;
Marcos, MAG ;
Bellas, C ;
Fernández-Cañadas, S ;
Cuevas, M ;
Sánchez, A ;
Velasco, JL ;
Navarro, JL ;
San Miguel, JF .
BLOOD, 1998, 91 (08) :2731-2736